No GLP-1 therapy is PBS-subsidised, meaning the medicines, costing hundreds of dollars per month, are not an option for many with obesity, which disproportionately affects low and middle-income individuals
peripheral atherosclerotic disease) who cannot be diagnosed with FH according to the Dutch criteria, although they have lipid disorders and do not achieve their LDL-C targets, according to the adopted guidelines (), and in whom all other standard therapies have failed (for at least 3 months) or are poorly tolerated, and/or there are contraindications to pharmacological treatment (adverse effects, complications, e.g
Clinical trials are underway to test these preliminary signals and determine whether GLP-1 analogs can reduce symptoms for people with depression, schizophrenia, addiction, and bipolar disorderalong with neurological conditions like Alzheimers disease and Parkinsons disease
Limbutara, K., Chou, C
D., Zaman, M., & Wan, M